人間の胃腸がんにおける体変異の免疫性
Eric Tran1, Mojgan Ahmadzadeh1, Yong-Chen Lu1
1Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
まとめ
ヒトの免疫システムは 胃腸がんの腫瘍変異を 頻繁に認識します 研究者達は 患者特有の癌変異を標的とした 特定のT細胞を発見し パーソナライズされた免疫療法への道を切り開きました
科学分野:
- 免疫学
- 腫瘍学
- 遺伝学
背景:
- 一般的な上皮がんにおけるT細胞反応の頻度はほとんど不明である.
- これらの反応を理解することは 効果的ながん免疫療法の開発に不可欠です
研究 の 目的:
- ヒトの免疫系が,一般的な上皮がんにおける腫瘍特異変異に対するT細胞反応を頻繁に発生させるかどうかを調査する.
- 転移性胃腸がん患者の腫瘍浸透性リンパ球 (TILs) によって認識される新皮質を特定する.
主な方法:
- 次の世代のシーケンシングと高通量免疫学的スクリーニングを使用しています.
- 転移性胃腸がん患者の腫瘍浸透性リンパ球 (TILs) の分析
主要な成果:
- 10人中9人の患者のTILは,体内の変異から派生した1〜3つの新エピトープを認識しました.
- 患者間で共用された免疫原性エピトープは特定されなかった.
- 一人の患者では,KRAS ((G12D)) ホットスポット変異特有のT細胞受容体が特定されました.
結論:
- 胃腸がんを患っている患者の多くには免疫遺伝子の変異がある.
- これらの発見は,患者特有の腫瘍変異を標的としたパーソナライズされた免疫療法の開発を支持する.
- KRAS ((G12D)) 固有のT細胞受容体の特定は,潜在的な治療標的を強調しています.
さらに関連する動画
07:21Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
2.7K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
12.4K
関連する概念動画
Mutagenicity and Carcinogenicity
2.1K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K
Cancers Originate from Somatic Mutations in a Single Cell
15.5K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.5K
Cancers Originate from Somatic Mutations in a Single Cell
3.4K
3.4K
Mismatch Repair
7.0K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
7.0K
Mouse Models of Cancer Study
6.7K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.7K
